Insider Transactions of Kymera Therapeutics, Inc. (KYMR)

Nello Mainolfi, CEO and Director of Kymera Therapeutics, Inc., executed several transactions on July 7, 2026, under a Rule 10b5-1 trading plan. Mainolfi acquired 50,000 shares of Common Stock at $2.08 per share, increasing his post-transaction holdings to 716,568 shares. Concurrently, he disposed of 50,000 shares of Common Stock at $119.00 per share, reducing his holdings to 666,568 shares. Additionally, Mainolfi exercised stock options, disposing of 45,559 options with a conversion/exercise price of $2.08, leaving him with 90,000 shares in that option lot. He also disposed of another 4,441 stock options at the same exercise price, resulting in 14,284 shares in that lot. These option exercises were for the right to buy Common Stock, with the underlying shares being fully vested and exercisable.